Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2017

Date: November 14, 2017
Pages: 369
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M1F0D75F932EN
Leaflet:

Download PDF Leaflet

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2017, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 16, 12, 1, 70, 32 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 22 and 22 molecules, respectively.

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Overview
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Development
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Assessment
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Companies Involved in Therapeutics Development
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drug Profiles
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AbbVie Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Absynth Biologics Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Actelion Pharmaceuticals Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Adenium Biotech ApS, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Alchemia Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Allergan Plc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AmpliPhi Biosciences Corp, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Antibiotx ApS, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aphios Corp, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Atriva Therapeutics GmbH, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bavarian Nordic A/S, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bharat Biotech International Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by C3J Therapeutics Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cadila Pharmaceuticals Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Citius Pharmaceuticals Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Common Pharma Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ContraFect Corp, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Crestone Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Critical Outcome Technologies Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CrystalGenomics Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Debiopharm International SA, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Dermala Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by DesignMedix Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Destiny Pharma Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Emergent BioSolutions Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ensol Biosciences Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by GangaGen Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by GlaxoSmithKline Plc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helix BioMedix Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helperby Therapeutics Group Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Hsiri Therapeutics LLC, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Immupharma Plc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by iNtRON Biotechnology Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ioGenetics Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lakewood-Amedex Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lead Discovery Center GmbH, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by LegoChem Biosciences Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lipocure Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Madam Therapeutics BV, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Melinta Therapeutics Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Merck & Co Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Microbiotix Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MicuRx Pharmaceuticals Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MorphoSys AG, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nabriva Therapeutics plc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nemus Bioscience Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Novabiotics Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovaDigm Therapeutics Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Novalex Therapeutics Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Novan Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovoBiotic Pharmaceuticals LLC, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Oragenics Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ovensa Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Pfizer Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Phico Therapeutics Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by PolyPid Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Prommune Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Recce Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Savara Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sealife PHARMA GMBH, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sorrento Therapeutics Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Taejoon Pharm Co Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TAXIS Pharmaceuticals Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Telephus Medical LLC, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Theravance Biopharma Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Trellis Bioscience Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Valevia UK Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Venus Medicine Research Center, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by VLP Biotech Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Wockhardt Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by XBiotech Inc, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Yungjin Pharm Co Ltd, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H2 2017 (Contd..1), H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H2 2017 (Contd..2), H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H2 2017 (Contd..3), H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H2 2017 (Contd..4), H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects, H2 2017 (Contd..5), H2 2017
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

AbbVie Inc
Absynth Biologics Ltd
Actelion Pharmaceuticals Ltd
Adenium Biotech ApS
Alchemia Ltd
Allergan Plc
AmpliPhi Biosciences Corp
Antibiotx ApS
Aphios Corp
Aridis Pharmaceuticals LLC
Atriva Therapeutics GmbH
Bavarian Nordic A/S
Bharat Biotech International Ltd
C3J Therapeutics Inc
Cadila Pharmaceuticals Ltd
Citius Pharmaceuticals Inc
Common Pharma Inc
ContraFect Corp
Crestone Inc
Critical Outcome Technologies Inc
CrystalGenomics Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Dermala Inc
DesignMedix Inc
Destiny Pharma Ltd
Dong-A Socio Holdings Co Ltd
Emergent BioSolutions Inc
Ensol Biosciences Inc
GangaGen Inc
GlaxoSmithKline Plc
Helix BioMedix Inc
Helperby Therapeutics Group Ltd
Hsiri Therapeutics LLC
Ildong Pharmaceutical Co Ltd
Immupharma Plc
iNtRON Biotechnology Inc
ioGenetics Inc
Kyorin Pharmaceutical Co Ltd
Lakewood-Amedex Inc
Lead Discovery Center GmbH
LegoChem Biosciences Inc
Lipocure Ltd
Madam Therapeutics BV
Melinta Therapeutics Inc
Merck & Co Inc
Microbiotix Inc
MicuRx Pharmaceuticals Inc
MorphoSys AG
Nabriva Therapeutics plc
Nemus Bioscience Inc
Novabiotics Ltd
NovaDigm Therapeutics Inc
Novalex Therapeutics Inc
Novan Inc
NovoBiotic Pharmaceuticals LLC
Oragenics Inc
Ovensa Inc
Pfizer Inc
Phico Therapeutics Ltd
PolyPid Ltd
Prommune Inc
Recce Ltd
Savara Inc
Sealife PHARMA GMBH
Sorrento Therapeutics Inc
Taejoon Pharm Co Ltd
TAXIS Pharmaceuticals Inc
Telephus Medical LLC
Tetraphase Pharmaceuticals Inc
Theravance Biopharma Inc
Trellis Bioscience Inc
Valevia UK Ltd
Venus Medicine Research Center
VLP Biotech Inc
Wockhardt Ltd
XBiotech Inc
Yungjin Pharm Co Ltd
Skip to top


Ask Your Question

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: